Figure 5

EP2-PKA pathway is important in LPS-stimulated NO production and triptolide inhibition. (A) Primary rat microglial cells were treated with LPS (0.01 μg/mL), LPS plus AH6809 (10 μM), LPS plus triptolide (50 nM), LPS plus triptolide plus AH6809, and LPS plus triptolide plus butaprost (0.1 μM) for 24 h. At the end of the incubation period, the supernatants were collected for NO measurements. (B) Primary rat microglial cells were treated with LPS (0.01 μg/mL), LPS plus triptolide (50 nM), LPS plus triptolide plus butaprost (0.1 μM), LPS plus triptolide plus 8-CPT (10 μM), or LPS plus triptolide plus 6Bnz (10 μM) for 24 h. At the end of the incubation period, the supernatants were collected for NO measurements. (C) BV2 cells were treated with LPS (0.01 μg/mL), LPS plus triptolide (50 nM), LPS plus triptolide plus 6Bnz (10 μM), and LPS plus triptolide plus 6Bnz (10 μM) plus KT5720 (1 μM) for 24 h. At the end of the incubation period, the supernatants were collected for NO measurements. *P < 0.05 and ***P < 0.001.